

QUARTERLY INVESTMENT REVIEW

Equity Dislocation Investment Fund USD Class A

Performance returns (USD)

ANNUALIZED RETURNS (QUARTER-END)	Quarter-End	YTD	1-Year	3-Year	5-Year	10-Year	Since Inception
Equity Dislocation Investment Fund USD Class A (net)	3.39	3.39	-2.74	2.96	-	-	2.44
Equity Dislocation Investment Fund USD Class A (gross)	3.94	3.94	-0.62	5.22	-	-	4.74
FTSE 3-Mo. T-Bill	1.10	1.10	5.19	4.42	-	-	3.41
Value Add	+2.29	+2.29	-7.93	-1.46	-	-	-0.96

Data Source: GMO

MAJOR PERFORMANCE DRIVERS

For the first quarter of 2025, MSCI ACWI returned -1.3%, with MSCI ACWI Value outperforming with a return of 4.8% and MSCI ACWI Growth underperforming with a return of -6.8%. The Equity Dislocation Investment Fund aims to be dollar and (broadly) beta neutral and, for the quarter, it had an average long exposure of 101.9% and an average short exposure of 101.6%. The long portfolio performed a little behind ACWI Value, while the short portfolio also detracted alpha as it had much better performance than ACWI Growth. However, the poor performance of ACWI Growth was heavily impacted by the faltering Magnificent Seven, with the cohort down broadly 15% for the quarter. With the notable exception of Tesla, we don't believe that this is a group that are egregiously expensive enough to short. The net for the Equity Dislocation Investment Fund was, therefore, behind MSCI ACWI Value's 11.6% performance versus MSCI ACWI Growth for the quarter. Since inception, the portfolio remains ahead of ACWI Value minus ACWI Growth, and we are very pleased by the strong return profile. We believe that the opportunity set remains extremely compelling.

For the quarter, stock selection within countries across the long book added 280 bps relative to MSCI ACWI, driven by Denmark (70 bps), Thailand (50 bps), the Netherlands (50 bps), and the U.S. (40 bps), with the largest offsetting detractions from Germany (-30 bps) and China (-30 bps). Stock selection in the short book had a total positive impact against MSCI ACWI of 120 bps. The biggest detractors were the U.S. (-80 bps), Canada (-70 bps), and China (-40 bps), while the biggest contributions came from Germany (50 bps), Australia (40 bps), Italy (40 bps), and the UK (40 bps). There were some modest country bets, although these are typically residuals driven by bottom-up security selection. The biggest net long position was a 2.0% long exposure to Denmark, and the biggest net short position was a 1.8% short exposure to the UK. In aggregate, a lot of small losses meant that country positions had a -80 bp impact on performance for the first quarter.

RISKS

Risks associated with investing in the Fund may include: (1) Market Risk - Equities: the market price of equities may decline due to factors affecting the issuer, its industries, or the economy and equity markets generally. Declines in stock market prices generally are likely to reduce the net asset value of the Fund's shares; (2) Short Investment Exposure Risk: a Fund will incur a loss as a result of a short sale if the price of the security, currency or other instrument increases between the date of the short sale and the date on which the Fund replaces the borrowed security, currency or other instrument. Conversely, the Fund will realize a gain if the price of the security, currency or other instrument declines between those dates. The amount of any gain will be decreased, and the amount of any loss increased, by the amount of the premium, dividends or interest the Fund may be required to pay in connection with a short sale. Short selling exposes a Fund to unlimited risk with respect to that security, currency or other instrument due to the lack of an upper limit on the price to which an investment can rise; and (3) Non-U.S. Investment Risk: the market prices of many non-U.S. securities (particularly of companies tied economically to emerging countries) fluctuate more than those of U.S. securities. Many non-U.S. markets (particularly emerging markets) are less stable, smaller, less liquid, and less regulated than U.S. markets, and the cost of trading in those markets often is higher than it is in U.S. markets. For a more complete discussion of these and other risks, please consult the Fund's Prospectus.

Inception Date: 10-May-21

Performance Returns: Performance for the year of inception is less than a full calendar year. Returns shown for periods greater than one year are on an annualized basis. To obtain performance information to the most recent month-end, visit www.gmo.com. **Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein.** Net of all fees and expenses after reimbursement by the Manager, but not transaction costs, if any. If certain expenses were not reimbursed, performance would be lower. Gross of fees, expenses and transaction costs, if any. If these fees, expenses and costs were included, performance would be lower. A dilution adjustment may be applied on a subscription or redemption of shares to reflect the costs of dealing in the Fund's assets. The return on investment in the Fund may increase or decrease as a result of currency fluctuations if an investor's investment is made in a currency other than that used in the past performance calculation. If the Fund holds assets in currencies other than the base currency of the Fund and/or you invest in a share class that is denominated in a different currency than the base currency of the Fund, subject to any hedging at share class or Fund level, the value of your investment may be impacted by changes in the relative prices of the relevant currencies. The use of financial derivative instruments by the Fund may result in increased gains or losses within the Fund. The portfolio is actively-managed, is not managed relative to a benchmark and uses the Index for performance comparison purposes only and, where applicable, to compute a performance fee.

Singapore Accredited Investors and Hong Kong Professional Investors Use Only.

UCITS HAVE NO GUARANTEED RETURN AND PAST PERFORMANCE DOES NOT GUARANTEE FUTURE PERFORMANCE.

YOUR CAPITAL IS AT RISK.

www.GMO.com

QUARTERLY INVESTMENT REVIEW

MAJOR PERFORMANCE DRIVERS CONT.

We are prepared to run modestly larger sector bets, up to about 10% net long or short, and the two biggest positions in this regard over the quarter were an 8.2% net long position in Financials and a -6.0% net short position in Industrials. Our sector positioning added 90 bps to performance. Stock selection across the long book was positive in seven of the eleven sectors, negative in one sector, and broadly flat in the other three sectors, adding 360 bps altogether. The main contributors were Consumer Discretionary (100 bps), Information Technology (70 bps), and Communication Services (70 bps). Stock selection in the short book was positive in four of the eleven sectors, broadly flat in two sectors, and negative in the other five, with an impact of -120 bps detracted from performance in aggregate. The positive impacts included Health Care (50 bps) and Financials (40 bps), while the detractors were Communication Services (-60 bps), Consumer Discretionary (-60 bps), Materials (-60 bps), Information Technology (-50 bps), and Industrials (-40 bps).

Four of the top five biggest contributors at the total portfolio level were long positions including Leonardo (Italy Industrials), Societe Generale (France Financials), CVS (U.S. Health Care), and Banco Santander (Spain Financials). On the flipside, one of the top five biggest detractors at the total portfolio level, ON Semiconductor (U.S. Information Technology), was a long position.

QUARTERLY INVESTMENT REVIEW

PRODUCT OVERVIEW

The GMO Equity Dislocation Investment Fund seeks high total return. It aims to own attractively valued equities while correspondingly shorting equities where we believe that valuations are reflective of implausible growth expectations. Currently, the Fund is long global Value, short global Growth, to take advantage of the exceptionally wide valuation spread between Value and Growth.

The eligible universe for both the long and short side spans the market capitalization spectrum and includes both developed and emerging markets. Utilizing GMO's proprietary Price to Fair Value model to actively select the cheapest and most expensive stocks, the portfolio is diversified across sectors, countries, and regions and is intended to be approximately beta neutral.

This is a marketing communication and a financial promotion. Past performance does not predict future returns.

IMPORTANT INFORMATION

This is a marketing communication and a financial promotion. This is not a contractually binding document. An investor should consider all of the Fund's characteristics including the investment objectives, risks, charges and expenses before investing. This and other important information can be found in the Fund's prospectus and the KIID/PRIIPs KID. To obtain a prospectus and the KIID/PRIIPs KID please visit www.gmo.com. Read the prospectus and the KIID/PRIIPs KID carefully before investing and do not base any final investment decision on this communication alone.

Comparator Index(es): The FTSE 3-Month Treasury Bill Index is an independently maintained and widely published index comprised of short-term U.S. Treasury bills.

The Fund is a sub-fund of GMO Investments ICAV, an umbrella fund with segregated liability between sub-funds, which is authorised by the Central Bank of Ireland (the "Central Bank") as a UCITS pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, as amended. The authorisation of the ICAV is not an endorsement or guarantee of the ICAV by the Central Bank. Neither the Central Bank nor the UK's Financial Conduct Authority has approved and or takes responsibility for the contents of this document or for the financial soundness of the Fund or for the ICAV. THE ICAV is an EEA UCITS scheme which is recognised under Part 6 of The Collective Investment Schemes (Amendment etc.) (EU Exit) Regulations 2019, as amended.

GMO UK Limited Authorised and Regulated by the Financial Conduct Authority Registered no 4658801 England. GMO Netherlands is registered with the AFM.

The Fund has not been registered under the United States Investment Company Act of 1940, as amended, nor the U.S. Securities Act of 1933, as amended. None of the shares may be offered or sold, directly or indirectly, in the U.S. or to any U.S. Person, unless the securities are registered under the Act or an exemption from the registration requirements of the Act is available. A U.S. Person is defined as (a) any individual who is a citizen or resident of the U.S. for federal income tax purposes; (b) a corporation, partnership, or other entity created or organized under the laws of or existing in the U.S.; (c) an estate or trust the income of which is subject to U.S. federal income tax regardless of whether such income is effectively connected with a U.S. trade or business.

Investors and potential investors can also obtain the prospectus and key investor information, and a summary of investor rights and information on access to collective redress mechanisms, in English and local languages where the Fund is registered, at the following website:

<https://www.gmo.com/europe/product-index-page/alternatives/equity-dislocation-strategy/equity-dislocation-investment-fund/>

Please note that the management company of the Fund may decide to terminate the arrangements made for the marketing of the Fund in one or more EU member states pursuant to the UCITS marketing passport in accordance with the procedure provided for under the applicable laws that implement Article 93a of Directive 2009/65/EC (the UCITS Directive).

A full list of fees and charges applied to investment can be found in the prospectus and in the KIID/PRIIPs KID, available at: <https://www.gmo.com/europe/product-index-page/alternatives/equity-dislocation-strategy/equity-dislocation-investment-fund/>

This advertisement has not been reviewed by the Monetary Authority of Singapore.

UCITS HAVE NO GUARANTEED RETURN AND PAST PERFORMANCE DOES NOT GUARANTEE FUTURE PERFORMANCE.

Singapore Accredited Investors and Hong Kong Professional Investors Use Only.

ABOUT GMO

Founded in 1977, GMO is a global asset manager committed to delivering superior performance and advice to our clients. We are privately owned, which allows us to singularly focus on our sole business – achieving outstanding long-term client investment outcomes. Offering multi-asset, equity, fixed income, and alternative strategies, we invest with a long-term, valuation-based philosophical approach.

AMSTERDAM

BOSTON

LONDON

SAN FRANCISCO*

SINGAPORE

SYDNEY

TOKYO**

*GMO's West Coast Hub is comprised of members of Investment, Global Client Relations, and other teams located in and around the Greater San Francisco area

**Representative Office

www.GMO.com